- Home
- CLW vs FULC Comparison
CLW vs FULC Comparison
Compare CLW & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLW
- FULC
- Stock Information
- Founded
- CLW 2005
- FULC 2015
- Country
- CLW United States
- FULC United States
- Employees
- CLW N/A
- FULC N/A
- Industry
- CLW Paper
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- CLW Basic Materials
- FULC Health Care
- Exchange
- CLW Nasdaq
- FULC Nasdaq
- Market Cap
- CLW 348.3M
- FULC 372.2M
- IPO Year
- CLW N/A
- FULC 2019
- Fundamental
- Price
- CLW $22.07
- FULC $7.50
- Analyst Decision
- CLW Buy
- FULC Buy
- Analyst Count
- CLW 1
- FULC 8
- Target Price
- CLW $36.00
- FULC $7.13
- AVG Volume (30 Days)
- CLW 175.6K
- FULC 398.4K
- Earning Date
- CLW 11-03-2025
- FULC 11-12-2025
- Dividend Yield
- CLW N/A
- FULC N/A
- EPS Growth
- CLW 345.10
- FULC N/A
- EPS
- CLW 12.12
- FULC N/A
- Revenue
- CLW $1,550,400,000.00
- FULC N/A
- Revenue This Year
- CLW $12.75
- FULC N/A
- Revenue Next Year
- CLW $1.60
- FULC N/A
- P/E Ratio
- CLW $1.74
- FULC N/A
- Revenue Growth
- CLW 34.73
- FULC 2752.05
- 52 Week Low
- CLW $20.84
- FULC $2.32
- 52 Week High
- CLW $33.57
- FULC $8.50
- Technical
- Relative Strength Index (RSI)
- CLW 46.66
- FULC 61.05
- Support Level
- CLW $21.07
- FULC $6.69
- Resistance Level
- CLW $22.70
- FULC $7.50
- Average True Range (ATR)
- CLW 0.62
- FULC 0.41
- MACD
- CLW 0.20
- FULC 0.07
- Stochastic Oscillator
- CLW 50.57
- FULC 76.32
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.